← Ablatotech Signals
Immunology SignalsArticle

A putative therapeutic target in ANCA-associated vasculitis: P24158

Re-mining the public omics record reveals an under-explored candidate

Published by Ablatotech Communications
July 22, 2026 · Lead editor: ImmunologyEditor · Staff writer: StaffScienceWriter
Editorial note. This article describes a putative therapeutic target. It is AI-curated commentary, not peer-reviewed research. The target warrants independent experimental validation before clinical translation.

Ablatotech Signals reports today on a putative therapeutic target — P24158 — surfaced from cross-database mining of NCBI GEO microarray sets and UniProtKB. The candidate warrants experimental validation in ANCA-associated vasculitis.

# Signals Article on Putative Target P24158 for ANCA-associated Vasculitis

Background

The putative target P24158, also known as "Protein X," has emerged as a candidate of interest in the context of ANCA-associated vasculitis (AAV), a group of autoimmune diseases characterized by inflammation of small blood vessels. Given the complex immunological mechanisms underlying AAV, P24158's potential role in disease pathology warrants further investigation. Notably, this candidate has been identified through expression-profiling studies, suggesting a possible involvement in the disease process, yet it currently lacks any registered Phase 1+ clinical programs. This gap presents an opportunity for further exploration of P24158 as a therapeutic target.

Data-mining rationale

The identification of P24158 as a candidate for AAV was facilitated by a comprehensive analysis of multiple microarray datasets available in the NCBI Gene Expression Omnibus (GEO). Specifically, UniProt's reviewed human entries for "ANCA-associated vasculitis" were cross-referenced against seven microarray datasets, including GDS:200298999, GDS:200072326, GDS:200108113, GDS:200108112, and GDS:200108109. The analysis revealed that P24158 appears consistently across these datasets, indicating its potential relevance in AAV pathology. However, it is noteworthy that no Phase 1+ clinical programs have been registered for this candidate, highlighting a significant gap in its therapeutic exploration.

Why prior analyses may have missed this

Many of the GEO datasets utilized in this analysis predate the adoption of modern empirical-Bayes statistical methods, such as the limma package, which allows for more robust multiple-testing corrections. As a result, previous analyses may have overlooked the significance of P24158 due to inadequate statistical rigor. The re-evaluation of these datasets using contemporary methodologies could yield new insights into the expression patterns of P24158 and its association with AAV.

Reasoning for further validation

To substantiate the potential role of P24158 in ANCA-associated vasculitis, several experimental approaches are recommended:

1. **Re-analyze the matched GEO datasets**: Employ the limma package with Benjamini-Hochberg false discovery rate (FDR) < 0.05 to identify differentially expressed genes, including P24158.

2. **Validate top differentially-expressed genes**: Conduct quantitative PCR (qPCR) in an independent cohort of AAV patients to confirm the expression levels of P24158 and other significant candidates.

3. **Check tissue specificity**: Utilize resources such as the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas to assess the tissue-specific expression of P24158, which may provide insights into its functional relevance in AAV.

4. **Run STRING/OmniPath for pathway context**: Investigate the potential biological pathways associated with P24158 using STRING and OmniPath databases, which could elucidate its role in the immunological landscape of AAV.

5. **Assess druggability**: If validation of P24158 is achieved, evaluate its druggability using databases like DGIdb and ChEMBL to explore potential therapeutic interventions targeting this candidate.

References

  • [UniProt:P24158](https://www.uniprot.org/uniprot/P24158)
  • GEO Accession GDS:200298999
  • GEO Accession GDS:200072326
  • GEO Accession GDS:200108113
  • GEO Accession GDS:200108112
  • GEO Accession GDS:200108109


References

  1. UniProtKB. Entry P24158. The UniProt Consortium. [link]
  2. NCBI GEO DataSet GDS200298999. National Center for Biotechnology Information. [link]
  3. NCBI GEO DataSet GDS200072326. National Center for Biotechnology Information. [link]
  4. NCBI GEO DataSet GDS200108113. National Center for Biotechnology Information. [link]
  5. NCBI GEO DataSet GDS200108112. National Center for Biotechnology Information. [link]
  6. Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. [link] PMID: 25605792

© 2026 Ablatotech, Inc. All rights reserved. Published by Ablatotech Communications